Navigation Links
Intra-Cellular Therapies Cleared for Quotation on OTCQB
Date:12/19/2013

NEW YORK, Dec. 19, 2013 /PRNewswire/ -- Intra-Cellular Therapies, Inc. ("ITI"), a biopharmaceutical company focused on the development of therapeutics for CNS disorders, announced that its common stock has been approved for quotation on the OTC Markets – OTCQB tier (OTCQB) under the symbol "ITCI", and is expected to begin trading on December 20, 2013.

ABOUT INTRA-CELLULAR THERAPIES

Intra-Cellular Therapies (the "Company") is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disease and other disorders of the central nervous system ("CNS").  The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia and other neuropsychiatric and neurological disorders.  In December 2013, the Company announced positive topline results from the Company's randomized, placebo- and active-controlled Phase II clinical trial of ITI-007 in patients with acutely exacerbated schizophrenia.  In this study, ITI-007 met the trial's pre-specified primary endpoint, improving symptoms associated with schizophrenia as measured by a statistically significant and clinically meaningful decrease in the Positive and Negative Syndrome Scale (PANSS) total score.  The trial also met key secondary outcome measures related to efficacy on PANSS subscales and safety. In the Phase II trial, ITI-007 exhibited a differentiating response profile across a broad range of symptoms that we believe is consistent with improvements in social functioning deficits.

The Company is also developing other drug candidates.  In February 2011, the Company entered into a collaboration with the Takeda Pharmaceutical Company to develop certain phosphodiesterase 1 (PDE1) inhibitors for the treatment of cognitive deficits in schizophrenia and other CNS disorders.  In February 2013, the Company announced the successful completion of a Phase I single rising dose study of the lead
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intra-Cellular Therapies Announces Closing of $60 Million Private Placement and Completion of Reverse Merger
2. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
3. Immunotherapies Will Continue to Dominate the Malignant Melanoma Drug Market with Sales of Immune Checkpoint Inhibitors Accounting for Majority of Sales in this Drug Class in 2022
4. The Leukemia & Lymphoma Societys (LLS) Greater Bay Area Chapter to Host the 2014 Emerging Therapies & Survivorship Conference
5. Sangamo BioSciences Presents Data From Non-Human Primates Providing Proof Of Concept For Disruptive And Broadly Leverageable Platform For Protein Replacement Therapies
6. Improved Efficacy, Limited Toxicity of Targeted Therapies Brighten the Future of Treatment for Chronic Lymphocytic Leukemia
7. Innovative Compounds, Combination Therapies Improve Care of Patients with Wide Range of Blood Disorders
8. Study Confirms Efficacy of Innovative Therapies Quantum Negative Pressure Wound Therapy (NPWT) in Enhancing Wound Healing
9. Contrasting Reimbursement Environments Result in Different Prescribing Patterns for Premium-Priced Therapies in China and South Korea
10. U.S. Claims Data Show Declining Use of Platform Injectables as Oral Multiple Sclerosis Therapies Gain Traction
11. In the Psoriasis Drug Market, Continued Uptake of Janssens Stelara and the Launch of Emerging Systemic Therapies Will Drive Sales Growth to Nearly $9.2 Billion in 2022
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... Calif. , March 30, 2015  The investigational ... agent to alleviate certain menopause symptoms, such as hot ... March Journal of Women,s Health .[i] ... S- equol for menopausal vasomotor symptoms and possibly ... supporting safety of S- equol, physicians and health ...
(Date:3/30/2015)... Mar. 26, 2015 Research and Markets ... the addition of the "Urological Catheters ... to their offering. This report ... in Thousand Units and US$ Thousands by ... Catheters, & Peritoneal Catheters), and Urinary Catheters ...
(Date:3/30/2015)... 2015 Research and Markets ( ... "Marine Biotechnology - Global Strategic Business Report" ... estimates and forecasts are provided for the period ... is provided for these markets. Market data and ... This report analyzes the worldwide markets ...
Breaking Medicine Technology:New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 2New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 3New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 4New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 5New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 6Urological Catheters - Global Strategic Business Report 2015-2020: Burgeoning Ageing Populace to Propel Catheter Usage 2Urological Catheters - Global Strategic Business Report 2015-2020: Burgeoning Ageing Populace to Propel Catheter Usage 3Urological Catheters - Global Strategic Business Report 2015-2020: Burgeoning Ageing Populace to Propel Catheter Usage 4Urological Catheters - Global Strategic Business Report 2015-2020: Burgeoning Ageing Populace to Propel Catheter Usage 5Urological Catheters - Global Strategic Business Report 2015-2020: Burgeoning Ageing Populace to Propel Catheter Usage 6Urological Catheters - Global Strategic Business Report 2015-2020: Burgeoning Ageing Populace to Propel Catheter Usage 7Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 2Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 3Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 4Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 5Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 6Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 7
... Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced completion ... has now completed the final trial necessary to support a ... an NDA in the first half of 2011.  LEVADEX is ... 3 clinical development for the acute treatment of migraine. ...
... 21, 2010 Bellicum Pharmaceuticals, Inc. today announced $3 ... be used to prepare for Phase II trials of ... prostate cancer (mCRPC), and CaspaCIDe™, a cell therapy safety ... therapy (HSCT) setting. The new funding brings ...
Cached Medicine Technology:MAP Pharmaceuticals Announces Completion of LEVADEX™ Open-Label Safety Trial 2MAP Pharmaceuticals Announces Completion of LEVADEX™ Open-Label Safety Trial 3Bellicum Pharmaceuticals Announces $3 Million in Convertible Note Funding 2
(Date:3/30/2015)... FMC Corporation’s Health and Nutrition division ... Epax® Ultra and Core concentrates manufactured in the ... ensures the manufacturing process and all physical raw ... for Halal. , The new Halal certification ... advance its customer service to a global market ...
(Date:3/30/2015)... CA (PRWEB) March 30, 2015 On ... blue polo for yellow to inspire courage in Seth ... from Severe Combined Immunodeficiency (SCID). SCID causes affected individuals ... marrow transplant is needed to allow the development of ... transplant last Friday, created a video with his family ...
(Date:3/30/2015)... GenSight ®, provider of an ... a leader in The Forrester Wave™: Strategic Planning For ... The independent report positions GenSight as a leader and ... of 5) for the analytics, corporate strategy, assessment, direction ... GenSight’s position in the Leaders category. , According to ...
(Date:3/30/2015)... York, NY (PRWEB) March 30, 2015 V/NO ... that includes a convenient flute for opening/closing and for reuse. ... wine on the go. Health-conscious New Yorkers, professionals, and basically ... is sophisticated yet delicious to kick back socially or pair ... arise. , “ V/NO is dealcoholized wine and that ...
(Date:3/30/2015)... The “Orthopedic Software Market [By ... By Applications (Orthopedic Surgery, Joint Replacement, Fracture ... – Global Forecast to 2020” analyzes and ... in North America, Europe, Asia-Pacific and the ... before Buying: http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=94720371 , This ...
Breaking Medicine News(10 mins):Health News:FMC Health and Nutrition Announces Halal Certification for Epax® Brand Omega-3 Ingredients 2Health News:24Hr HomeCare Staff Hosts #WearYellowForSeth Campaign for Five-Year-Old Boy with Severe Combined Immunodeficiency 2Health News:GenSight Named as a Leader by Independent Research Firm in the Strategic Planning Market 2Health News:GenSight Named as a Leader by Independent Research Firm in the Strategic Planning Market 3Health News:Napa Valley Alcohol-Removed Red, White & Rosé Wines Have Launched. 2Health News:The Global Orthopedic Software Market is Expected to Reach $308.5 Million by 2020 – Report Published by MarketsandMarkets 2Health News:The Global Orthopedic Software Market is Expected to Reach $308.5 Million by 2020 – Report Published by MarketsandMarkets 3Health News:The Global Orthopedic Software Market is Expected to Reach $308.5 Million by 2020 – Report Published by MarketsandMarkets 4
... Fund and Sustain to Raise ... Donations after Floods, ... the decimation of a number of organic and family farms,in Minnesota ... farmers, nonprofits, restaurants and natural,food cooperatives to implement a multifaceted, region-wide ...
... Meeting Expectations today announced,that it has been ... of the industry,s,largest and most influential full-service independent ... corporate market. Compiled by,Penton Media,s Corporate Meetings & ... billion corporate meetings and events,industry, the CMI 25 ...
... of us have never heard of immune infertility, yet ... Immune infertility is one of 80 autoimmune disorders, a ... Type 1 Diabetes. This reproductive disorder affects both men ... on sperm. , A recent discovery at the University ...
... N.J., Sept. 12 Leaders of the,medical community ... association to address increasing concerns that the quality ... of the practice of medicine, are,in jeopardy. ... was,created to provide a strong, unified voice for ...
... Medina General Hospital and,University Hospitals announced today ... which Medina General has indicated its desire to ... network of,community- based hospitals. The agreement is subject ... regulatory and governance approvals. "We,re excited about ...
... joins Growing Company, METAIRIE, La., Sept. 12 ... orthodontic and dental practices,worldwide, has hired David Ward ... experience will be invaluable to serving our existing,doctors ... of our,company," said Chris Roussos, president and CEO ...
Cached Medicine News:Health News:Whole Foods Market(R) Donates $25,000, for Midwest Farmers - Hoping to Match an Additional $10,000, via Customer Donations 2Health News:Whole Foods Market(R) Donates $25,000, for Midwest Farmers - Hoping to Match an Additional $10,000, via Customer Donations 3Health News:Meeting Expectations Named to First Annual 'CMI 25' List by Corporate Meetings & Incentives Magazine 2Health News:UVA researchers find important clue to immune infertility 2Health News:New Jersey Physicians Launch New, Statewide Association to Fight for Stronger Voice in Healthcare 2Health News:Medina General Hospital and University Hospitals Agree to Pursue Affiliation 2Health News:David Ward Joins OrthoSynetics(TM) as Western Region Sales Manager 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: